Show simple item record

hal.structure.identifier
dc.contributor.authorGiret d'Orsay, Geneviève*
hal.structure.identifier
dc.contributor.authorMazières, Bernard*
hal.structure.identifier
dc.contributor.authorBard, Hervé*
hal.structure.identifier
dc.contributor.authorLigier, Marie*
hal.structure.identifier
dc.contributor.authorBrud, Isabelle*
hal.structure.identifierLaboratoire d'Economie de Dauphine [LEDa]
dc.contributor.authorLe Pen, Claude*
dc.date.accessioned2012-09-14T13:20:41Z
dc.date.available2012-09-14T13:20:41Z
dc.date.issued2007-10
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/9987
dc.language.isoenen
dc.subjectCost-benefit analysisen
dc.subjectMedicoeconomic analysisen
dc.subjectKnee osteoarthritisen
dc.subjectHyaluronic aciden
dc.subjectSuplasynen
dc.subject.ddc334en
dc.subject.classificationjelI12en
dc.subject.classificationjelI11en
dc.titleMedicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: The MESSAGE studyen
dc.typeArticle accepté pour publication ou publié
dc.description.abstractenIntroduction Medicoeconomic data on treatments for osteoarthritis are scant. We investigated the impact of hyaluronic acid therapy on the cost of management of knee osteoarthritis. Our primary objective was to compare medical costs (admissions, outpatient visits, investigations, and treatments) and non-medical costs (sick leaves and transportation) from the perspective of the national health insurance system during the 3 months before and the 6 months after three intraarticular injections of hyaluronic acid. Our secondary objective was to evaluate treatment benefits in terms of pain, function, and quality of life. Methods Observational, multicenter, longitudinal, before-after study of the medical and economic effects of hyaluronic acid therapy for symptomatic knee osteoarthritis. Results Of the 296 assessable patients (mean age, 69 years; 30% with obesity; 65% women), only 5% of patients were withdrawn prematurely from the study. Significant improvements in the Lequesne index were found 3 and 6 months after treatment; the improvement was greater than 50% in over half the patients. Pain and quality-of-life scores improved significantly. Total cost of the disease decreased from €334 for the 3 pretreatment months to €295 and €233 for posttreatment months 1–3 and 4–6, respectively. Conclusion The costs of knee osteoarthritis decreased during the 6 months after Suplasyn® therapy, indicating that the cost of the medication was more than offset by the decreased need for other treatments. Concomitantly, clinical benefits were obtained. Under the conditions of everyday practice, hyaluronic acid may provide medical benefits at an acceptable cost.en
dc.relation.isversionofjnlnameJoint Bone Spine
dc.relation.isversionofjnlvol74en
dc.relation.isversionofjnlissue5en
dc.relation.isversionofjnldate2007-10
dc.relation.isversionofjnlpages453–460en
dc.relation.isversionofdoihttp://dx.doi.org/10.1016/j.jbspin.2007.01.037en
dc.relation.isversionofjnlpublisherElsevieren
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record